

ICMJE DISCLOSURE FORM

Date: 2021-05-01

Your Name: Göran Rådegran

Manuscript Title: Plasma ADAMTS-13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Dr Rådegran is, and has been primary-, or co-, investigator in; clinical PAH trials for GlaxoSmithKline, Actelion Pharmaceuticals Sweden AB, Pfizer, Bayer, Janssen, Acceleron and United Therapeutics, and in clinical heart trans-plantation immuno-suppression trials for Novartis. Some article processing charges were provided by Lund University. Rådegran reports unrestricted research grants from ALF, Actelion Pharmaceuticals Sweden AB and a non-interventional investigator-initiated study research grant from Janssen-Cilag AB, during the conduct of the study.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	Indicated in #1 above.
3	Royalties or licenses	x None	

4	Consulting fees	<input type="checkbox"/> None	Dr. Rådegran reports personal lecture fees from Actelion Pharmaceuticals Sweden AB, Bayer Health Care, GlaxoSmithKline, Janssen-Cilag AB, Nordic Infucare and Orion Pharma outside the submitted work.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None	Indicated in #4 above.
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None	Dr. Rådegran is the president of the Swedish Association of Pulmonary Hypertension.
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.